Avaí Bio, Inc.

AI-generated fair value estimate for this company.

Method: Asset/NAV-based approach (DCF not usable — pre-revenue, no operating cash flow to project). As of latest 10-Q data: cash of $3,070 vs. debt of $745,523 (net debt of ~$742,453), total stockholders' equity of -$2.14M (negative), 137.26M shares outstanding, giving tangible book value per share of roughly -$0.016. Since net tangible assets are negative, a small nominal option value of $0.02/share is assigned to reflect the embedded call-option value of the company's early-stage encapsulated cell-therapy pipeline (diabetes, Klotho-based anti-aging) and AI assets/partnerships (Austrianova, San Raffaele Hospital), rather than a formal DCF output.

Reasoning: AVAI is a clinical/pre-clinical stage biotech-plus-AI micro-cap with no revenue, negative net income (-$1.91M TTM), negative equity, and minimal cash — a standard FCF-based DCF cannot be supported with real inputs. A liquidation/NAV-style approach is most defensible here, and it points to essentially no fundamental asset backing; the current market price appears to reflect speculative sentiment/news-driven trading rather than demonstrable value.